RAS proteins are crucial in cancer research, particularly due to their role in cellular signal transduction. As a family of small GTPases, RAS proteins, including HRAS, KRAS, and NRAS, are among the most common oncogenes in human cancers. KRAS mutations, notably G12C, G12D, G12V, G13D, and Q61H, are highly prevalent in certain cancers, making KRAS a vital target in oncology drug development.
The significance of RAS proteins in cancer is underscored by their involvement in regulating molecular events through their active (GTP-bound) and inactive (GDP-bound) forms. This regulatory function is key in controlling downstream signaling cascades that drive tumor growth and survival.
Amid Biosciences supports this critical area of research by offering an extensive range of recombinant biotinylated and non-biotinylated KRAS proteins, including KRAS "wild type" and various KRAS mutations. These proteins are essential tools for advancing drug discovery and medical research. Additionally, custom services for loading KRAS proteins with nucleotides or their analogs are available, further enhancing research capabilities.
To complement KRAS research, Amid Biosciences also provides key biomolecules involved in KRAS regulation, such as Raf1-RBD, PI3Kα-RBD, SOS1, Neurofibromin (NF1) and SHP2, as well as related proteins like RALA, RALB, Rheb, MEK1, and MEK2. These proteins are integral to understanding and targeting the RAS/MAP kinase signal transduction pathway, a critical pathway in cancer proliferation.
In summary, RAS proteins are not only pivotal in understanding cancer biology but also in developing targeted therapies. Amid Biosciences' comprehensive offerings in this area are instrumental in driving forward the research and development of new cancer treatments.
